These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

716 related articles for article (PubMed ID: 12408664)

  • 1. Growth characteristics of ChimeriVax-DEN2 vaccine virus in Aedes aegypti and Aedes albopictus mosquitoes.
    Johnson BW; Chambers TV; Crabtree MB; Bhatt TR; Guirakhoo F; Monath TP; Miller BR
    Am J Trop Med Hyg; 2002 Sep; 67(3):260-5. PubMed ID: 12408664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the replication kinetics of the ChimeriVax-DEN 1, 2, 3, 4 tetravalent virus mixture in Aedes aegypti by real-time reverse transcriptase-polymerase chain reaction.
    Johnson BW; Chambers TV; Crabtree MB; Guirakhoo F; Monath TP; Miller BR
    Am J Trop Med Hyg; 2004 Jan; 70(1):89-97. PubMed ID: 14971704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth characteristics of the chimeric Japanese encephalitis virus vaccine candidate, ChimeriVax-JE (YF/JE SA14--14--2), in Culex tritaeniorhynchus, Aedes albopictus, and Aedes aegypti mosquitoes.
    Bhatt TR; Crabtree MB; Guirakhoo F; Monath TP; Miller BR
    Am J Trop Med Hyg; 2000 Apr; 62(4):480-4. PubMed ID: 11220763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth characteristics of the veterinary vaccine candidate ChimeriVax-West Nile (WN) virus in Aedes and Culex mosquitoes.
    Johnson BW; Chambers TV; Crabtree MB; Arroyo J; Monath TP; Miller BR
    Med Vet Entomol; 2003 Sep; 17(3):235-43. PubMed ID: 12941006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth characteristics of ChimeriVax-Den vaccine viruses in Aedes aegypti and Aedes albopictus from Thailand.
    Higgs S; Vanlandingham DL; Klingler KA; McElroy KL; McGee CE; Harrington L; Lang J; Monath TP; Guirakhoo F
    Am J Trop Med Hyg; 2006 Nov; 75(5):986-93. PubMed ID: 17124001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.
    Guirakhoo F; Kitchener S; Morrison D; Forrat R; McCarthy K; Nichols R; Yoksan S; Duan X; Ermak TH; Kanesa-Thasan N; Bedford P; Lang J; Quentin-Millet MJ; Monath TP
    Hum Vaccin; 2006; 2(2):60-7. PubMed ID: 17012873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Replication of chimeric yellow fever virus-dengue serotype 1-4 virus vaccine strains in dendritic and hepatic cells.
    Brandler S; Brown N; Ermak TH; Mitchell F; Parsons M; Zhang Z; Lang J; Monath TP; Guirakhoo F
    Am J Trop Med Hyg; 2005 Jan; 72(1):74-81. PubMed ID: 15728870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vector competence of Aedes albopictus and Aedes aegypti (Diptera: Culicidae) for DEN2-43 and New Guinea C virus strains of dengue 2 virus.
    Guo XX; Zhu XJ; Li CX; Dong YD; Zhang YM; Xing D; Xue RD; Qin CF; Zhao TY
    Acta Trop; 2013 Dec; 128(3):566-70. PubMed ID: 23962388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limited potential for transmission of live dengue virus vaccine candidates by Aedes aegypti and Aedes albopictus.
    Sardelis MR; Edelman R; Klein TA; Innis BL; Putnak JR; Jones JW; Turell MJ
    Am J Trop Med Hyg; 2000 Jun; 62(6):698-701. PubMed ID: 11304057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vector competence of Aedes albopictus and Aedes aegypti (Diptera: Culicidae) for the DEN2-FJ10 and DEN2-FJ11 strains of the dengue 2 virus in Fujian, China.
    Guo XX; Li CX; Zhang YM; Xing D; Dong YD; Zhang HD; Qin CF; Zhao TY
    Acta Trop; 2016 Sep; 161():86-90. PubMed ID: 27260668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.
    Guirakhoo F; Weltzin R; Chambers TJ; Zhang ZX; Soike K; Ratterree M; Arroyo J; Georgakopoulos K; Catalan J; Monath TP
    J Virol; 2000 Jun; 74(12):5477-85. PubMed ID: 10823852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of temperature and Wolbachia infection on vector competence of potential dengue vectors Aedes aegypti and Aedes albopictus in the transmission of dengue virus serotype 1 in southern Taiwan.
    Tsai CH; Chen TH; Lin C; Shu PY; Su CL; Teng HJ
    Parasit Vectors; 2017 Nov; 10(1):551. PubMed ID: 29116011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes.
    Troyer JM; Hanley KA; Whitehead SS; Strickman D; Karron RA; Durbin AP; Murphy BR
    Am J Trop Med Hyg; 2001 Nov; 65(5):414-9. PubMed ID: 11716092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dengue 3 virus infection of Aedes albopictus and Aedes aegypti: comparison of parent and progeny candidate vaccine viruses.
    Schoepp RJ; Beaty BJ; Eckels KH
    Am J Trop Med Hyg; 1990 Jan; 42(1):89-96. PubMed ID: 2301711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substitution of wild-type yellow fever Asibi sequences for 17D vaccine sequences in ChimeriVax-dengue 4 does not enhance infection of Aedes aegypti mosquitoes.
    McGee CE; Tsetsarkin K; Vanlandingham DL; McElroy KL; Lang J; Guy B; Decelle T; Higgs S
    J Infect Dis; 2008 Mar; 197(5):686-92. PubMed ID: 18266608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine.
    Guirakhoo F; Arroyo J; Pugachev KV; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Soike K; Ratterree M; Monath TP
    J Virol; 2001 Aug; 75(16):7290-304. PubMed ID: 11462001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experimental infection of Culex annulirostris, Culex gelidus, and Aedes vigilax with a yellow fever/Japanese encephalitis virus vaccine chimera (ChimeriVax-JE).
    Reid M; Mackenzie D; Baron A; Lehmann N; Lowry K; Aaskov J; Guirakhoo F; Monath TP
    Am J Trop Med Hyg; 2006 Oct; 75(4):659-63. PubMed ID: 17038690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infection of Aedes albopictus and Aedes aegypti mosquitoes with dengue parent and progeny candidate vaccine viruses: a possible marker of human attenuation.
    Schoepp RJ; Beaty BJ; Eckels KH
    Am J Trop Med Hyg; 1991 Aug; 45(2):202-10. PubMed ID: 1877715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates.
    Guirakhoo F; Pugachev K; Arroyo J; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Draper K; Monath TP
    Virology; 2002 Jun; 298(1):146-59. PubMed ID: 12093182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the antigen distribution and tissue tropisms of three phenotypically distinct yellow fever virus variants in orally infected Aedes aegypti mosquitoes.
    McElroy KL; Girard YA; McGee CE; Tsetsarkin KA; Vanlandingham DL; Higgs S
    Vector Borne Zoonotic Dis; 2008 Oct; 8(5):675-87. PubMed ID: 18494601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.